日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

法匹拉韦（一种口服RNA依赖性RNA聚合酶抑制剂）治疗轻度至中度COVID-19的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验

期刊:International Journal of Infectious Diseases
影响因子:4.3
doi:10.1016/j.ijid.2020.11.142
Udwadia, Zarir F; Singh, Pawan; Barkate, Hanmant; Patil, Saiprasad; Rangwala, Shabbir; Pendse, Amol; Kadam, Jatin; Wu, Wen; Caracta, Cynthia F; Tandon, Monika
发表日期：2021
文献求助 收藏

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

阿克利溴铵/富马酸福莫特罗固定剂量组合的疗效和安全性：一项为期 24 周的随机、安慰剂对照 AUGMENT COPD 研究

期刊:Respiratory Research
影响因子:5
doi:10.1186/s12931-014-0123-0
D'Urzo, Anthony D; Rennard, Stephen I; Kerwin, Edward M; Mergel, Victor; Leselbaum, Anne R; Caracta, Cynthia F
COPD
慢性阻塞性肺疾病
发表日期：2014
文献求助 收藏

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

在慢性阻塞性肺疾病（COPD）患者中，阿克利溴铵/富马酸福莫特罗固定剂量复方制剂与各组分及安慰剂相比的疗效和安全性（ACLIFORM-COPD）：一项多中心随机研究

期刊:BMC Pulmonary Medicine
影响因子:2.8
doi:10.1186/1471-2466-14-178
Singh, Dave; Jones, Paul W; Bateman, Eric D; Korn, Stephanie; Serra, Cristina; Molins, Eduard; Caracta, Cynthia; Gil, Esther Garcia; Leselbaum, Anne
COPD
LIF
慢性阻塞性肺疾病
发表日期：2014
文献求助 收藏

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

阿克利定可改善慢性阻塞性肺疾病患者的运动耐力、呼吸困难、肺过度充气和身体活动能力：一项随机、安慰剂对照、交叉试验

期刊:BMC Pulmonary Medicine
影响因子:2.8
doi:10.1186/1471-2466-14-209
Beeh, Kai M; Watz, Henrik; Puente-Maestu, Luis; de Teresa, Luis; Jarreta, Diana; Caracta, Cynthia; Garcia Gil, Esther; Magnussen, Helgo
慢性阻塞性肺疾病
发表日期：2014
文献求助 收藏

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study

一项为期 6 周的随机、对照 IIIb 期研究比较了溴化阿克利铵与安慰剂和噻托溴铵治疗中重度慢性阻塞性肺疾病患者的疗效和安全性：

期刊:Copd-Journal of Chronic Obstructive Pulmonary Disease
影响因子:2.1
doi:10.3109/15412555.2013.814626
Beier, Jutta; Kirsten, Anne-Marie; Mróz, Robert; Segarra, Rosa; Chuecos, Ferran; Caracta, Cynthia; Gil, Esther Garcia
慢性阻塞性肺疾病
发表日期：2013
文献求助 收藏